hmpeducation.com Open in urlscan Pro
45.60.104.19  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main content


MAIN NAVIGATION

 * Specialties
   * Autoimmune
   * CardioVascular
   * Clinical Pathways
   * Dermatology
   * Gastroenterology
   * Neurology
   * Oncology
   * Population Health
   * Psychiatry & Behavioral Health
   * Emergency & Mobile Medicine
   * Rheumatology & Arthritis
   * Surgery
   * Wound Care
 * Events
 * Education
 * Log in



PLEASE LOGIN TO PARTICIPATE

Course HomeCourse Progress
 * Pre-Test
 * Access Webcast
 * Download PDF of Slides
 * Evaluation
 * Certificate

2020-03-02T11:02:25-05:00


THE HETEROGENEITY, THERAPEUTIC ADVANCEMENTS, AND UPDATED GUIDELINES FOR THE
TREATMENT OF RRMM





FACULTY

SHAM MAILANKODY, MBBS
Associate Attending Physician
Memorial Sloan Kettering Cancer Center
New York City, New York

ANDREW YEE, MD
Clinical Director
Center for Multiple Myeloma, Mass. General Cancer Center
Assistant Prof. of Medicine, Harvard Medical School
Boston, Massachusetts 


PROVIDER STATEMENT



Provided by HMP Education, an HMP Global Company.

For questions regarding this educational activity, or to cancel your account,
please call 609-371-1137 or email accreditation@hmpglobal.com.


INTENDED LEARNERS

This activity is designed for oncology healthcare professionals, including
physicians, nurse practitioners(NPs), physician assistants (PAs), nurses,
pharmacists, and other members of the multidisciplinary oncology care team,
particularly those who care for patients with RRMM.


LEARNING OBJECTIVES

After participating in this activity, learners should be better able to:

 * Evaluate the most recent clinical efficacy and safety data surrounding new
   and emerging therapeutics to develop treatment algorithms for patients with
   RRMM
 * Implement alternative treatment approaches and SOC according to current
   guideline recommendations in patients that continue to experience RRMM after
   multiple therapeutic attempts
 * Discuss mechanisms of action (MOAs), adverse events (AEs), and
   associated toxicities observed with novel and emerging therapies for RRMM
 * Assess barriers to optimal treatment and management of patients with RRMM
 * Describe advances in implementation of current and emerging antibody therapy
   strategies, protocols, and clinical pathways in the treatment and management
   of patients with RRMM


ACTIVITY OVERVIEW

This on-demand webcast is available with synchronized slides and video/audio. If
you claimed credit for the live program held on June 4, 2023 in Chicago,
Illinois, you are not eligible to claim credit for this enduring activity.

To be eligible for credit, participants must complete the educational activity
and complete the activity evaluation form. Upon completing the activity, there
will be instructions on how to complete the evaluation and print a certificate
or other documentation of credit.

Release Date: June 20, 2023
Expiration Date: June 20, 2024
Estimated Time to Complete: 1.50 hour

There is no fee associated with this activity.


HARDWARE/SOFTWARE REQUIREMENTS

The activity is best supported via a computer or device with current versions of
the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader
is required for print publications. 


CONTINUING EDUCATION

In support of improving patient care, HMP Education is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the healthcare
team.

Note: This statement is not an indication of approved credits. Please see below
for full accreditation details, including credit types and totals, for this
activity.


PHYSICIANS

HMP Education designates this internet enduring activity for a maximum of
1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.


PHARMACISTS

 

This internet enduring, knowledge-based activity (Universal Activity Number:
JA0006201-0000-23-095-H01-P) has been approved for a maximum of 1.50 contact
hours (.15 CEUs).

The certificate is not the official record of your participation in the
activity. The official record of credit will be the information in the CPE
Monitor system. Following ACPE Policy, HMP Education must transmit your claim to
CPE Monitor within 60 days from the date you complete this CPE activity. HMP
Education is not able to report your claimed credit after this 60-day period.
Eligibility for pharmacy credit is contingent upon the successful completion of
a post-test and/or evaluation for each activity or session attended.


NURSES

This continuing nursing education internet enduring activity awards 1.5 contact
hours.

Provider approved by the California Board of Registered Nursing, Provider #13255
for 1.5 contact hours. 


NURSE PRACTITIONERS

American Academy of Nurse Practitioners National Certification Program
accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.


PHYSICIAN ASSISTANTS

HMP Education has been authorized by the American Academy of PAs (AAPA) to award
AAPA Category 1 CME credits for activities planned in accordance with the AAPA
CME Criteria. This internet enduring activity is designated for 1.5 AAPA
Category 1 credits. Approval is valid until June 20, 2024. PAs should only claim
credit commensurate with the extent of their participation.


INTERNATIONAL RECOGNITION

The following Countries, Regions, and Accrediting Bodies accept, or have
reciprocity or mutual recognition of credits with the AMA/ACCME. Please contact
the accrediting body to find out more information on submitting or converting
your credits.

 * Bavarian Chamber of Physicians (Germany)
 * Bulgarian Union of Scientific Medical Societies (Bulgaria)
 * Canadian Medical Association (Canada)
 * Canadian Nurses Association (Canada)
 * EBAC® (European Board for Accreditation of Continuing Education for Health
   Professionals)
 * Federation of Royal Colleges of Physicians (UK)
 * French National Medical Council (France)
 * Italian Federation of Scientific Medical Societies (Italy)
 * National CME Commission of the Italian Ministry of Health (Italy)
 * Spanish Accreditation Council for CME (Spain)
 * UEMS-EACCME® (European Union of Medical Specialists)


USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand
names for participant clarity purposes only, due to the presence of different
branded versions of the same product. No product promotion or recommendation
should be inferred.


UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs
or devices that are not currently approved by the European Medicines Agency
(EMA) of the European Union or the Food and Drug Administration (FDA) of the
United States. Participants are strongly encouraged to consult approved product
labeling for any drug or device mentioned in this activity before use. The
opinions expressed during this activity are the opinions of the respective
authors, presenters or moderators and do not necessarily reflect the opinions of
HMP Education.


DISCLAIMERS

The material presented and related discussions are not intended to be medical
advice, and the presentation or discussion of such material is not intended to
create and does not establish a provider-patient relationship. Medical advice of
any nature should be sought from an individual’s own provider.

The opinions expressed in this educational activity are those of the faculty and
are not attributable to HMP Global or any of its subsidiaries or affiliates.
Clinical judgment must guide each professional in weighing the benefits of
treatment against the risk of toxicity. Dosages, indications, and methods of use
for products referred to in this activity are not necessarily the same as
indicated in the package insert for each product, may reflect the clinical
experience of the presenters, and may be derived from the professional
literature or other clinical sources. Consult complete prescribing information
before administering.


DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

HMP Education is an independent provider of continuing medical education. HMP
Education has no proprietary or financial interest in medical or healthcare
products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, HMP Education is committed to
ensuring balance, independence, objectivity, and scientific rigor for all
accredited continuing education. These policies include assigning relevance to,
and mitigating, all perceived or real relevant financial relationship (conflicts
of interest) between any individual with control over the content and any
ineligible company (commercial interest) as defined by the ACCME and CPME.

Any individual with control over accredited content, including planner, faculty,
and reviewer, is required to globally disclose:

 1. Individual relationship(s) or lack thereof, and its nature, with any/all
    ineligible company, and;
 2. Any investigational, off-label, or non-FDA approved content or discussion

HMP Education has reviewed these disclosures, assigned relevance based on the
relationship and scope of content, and identified those with the potential to
compromise the goals and educational integrity of the education. Relevant
relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate
identified financial relationships (conflicts of interest), and ensure:

 1. All recommendations involving clinical medicine is based on evidence that is
    accepted within the medical profession as adequate justification for their
    indications and contraindications in the care of patients.
 2. All scientific research referred to, reported, or used in accredited
    continuing education in support or justification of a patient care
    recommendation conforms to the generally accepted standards of experimental
    design, data collection, and analysis.
 3. Content is appropriate, fair and balanced, unbiased, referenced, and
    non-promotional.

All relevant financial relationships have been mitigated.

FACULTY

The faculty has reported the following:

Dr. Mailankody: Advisory Board—Evicore, Janssen, Legend Biotech, Optum; Research
Funding—Bristol Myers Squibb, Janssen

Dr. Yee: Consultant—AbbVie, Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK,
Janssen, Karyopharm, Oncopeptides, Regeneron, Sanofi, Takeda

CLINICAL REVIEWER

Anthony Mato, MD
Cayuga Cancer Center
Ithaca, New York

Dr. Mato: Consultant—AstraZeneca

PLANNING COMMITTEE

Susie Seaman, NP, MSN, CWCN, CWS (nurse planner)
Wound Clinic, Family Health Centers of San Diego
San Diego, California

Ms. Seaman has disclosed no relevant financial relationship with any ineligible
company (commercial interest).

HMP Education planners and staff include Kristin Ciszeski; Samantha Joy; Randy
Robbin; Lacey Schmeidler and Andrea Zimmerman, EdD.

No HMP Education planner or staff has disclosed a relevant financial
relationship with any ineligible company (commercial interest).


ADA STATEMENT

HMP Education complies with the legal requirements of the Americans with
Disabilities Act and the rules and regulations thereof. If any participant in
this educational activity needs accommodations, please call 609-371-1137.


PRIVACY POLICY

HMP Education protects the privacy of personal and other information regarding
participants, educational partners, and joint providers. HMP Education and our
joint providers will not release personally identifiable information to a third
party without the individual’s consent, except such information as is required
for reporting purposes to the appropriate accrediting agency. HMP Education
maintains physical, electronic, and procedural safeguards that comply with
federal regulations to guard your nonpublic personal information.

Copyright © 2023 by HMP Education. All rights reserved. No part of this
accredited continuing education activity may be reproduced or transmitted in any
form or by any means, electronic or mechanical, without first obtaining
permission from HMP Education.


GRIEVANCE POLICY

Any participant wanting to file a grievance with respect to any aspect of a
continuing education activity accredited by HMP Education may contact Samantha
Joy, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by
email at accreditation@hmpglobal.com or in writing at 104 Windsor Center Drive,
East Windsor, NJ 08520. Ms. Joy will review the grievance and respond within 30
days of receiving the complaint.


COMMERCIAL SUPPORT

Supported by an educational grant from Janssen Biotech, Inc., administered by
Janssen Scientific Affairs, LLC.

HMP GLOBAL PRODUCTS

 * Consultant 360
 * VRTX
 * HMP Global Learning Network

ABOUT

 * About HMP Education
 * Contact Us
   
 * Terms/Privacy

© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use